United Kingdom (UK)
Recombinant monoclonal antibody to PD-1. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 1H3.
UniProt Accession Number of Target Protein: Q15116
Alternative Name(s) of Target: CD279; PD1; PD 1; Programmed cell death protein 1; Programmed cell death 1; pdcd1; Protein PD-1; hPD-1
Immunogen: The original antibody was generated by immunizing mice with human PD-1-Fc.
Specificity: The antibody binds specifically to PD-1.
Application Notes: The original format of the antibody was able to bind to PD-1 expressed on the surfaces of CHO cells, as measured by median fluorescence intensity. The antibody exhibited neutralizing activity and recognized antigen. CHO cells transfected with human full length PD-1 were pre-incubated with the human chimeric version of the antibody and stained by biotin-labeled anti-hB7-H1-Fc or anti-hB7-DC mFc. The antibody could bind to the cells and block binding of B7-H1-Fc and B7-DC-Fc to cells expressing human PD-1. The chimeric version of the antibody exhibited an affinity KD of 2.19 nM. The EC50 of the construct was found to be 75 ng. The chimeric antibody demonstrated enhanced binding to both CD8 and CD4 cells. The chimeric version of the antibody was found to mediate approximately a 7-fold increase in T cell proliferation and approximately a 12 fold increase in IFN-γ production per cell. Humanized versions of the antibody were constructed. The specificity of the antibodies was confirmed by ELISA. The humanized antibodies could block interactions between PD-1-expressing HEK293 cells and B7-H1 (US11236141B2).
Antibody first published in: PMID: